폐 스텐트 시장 : 제품 유형, 적응증, 재료, 환자 연령층, 최종사용자별 - 세계 예측(2026-2032년)

The Lung Stents Market is projected to grow by USD 224.46 million at a CAGR of 5.69% by 2032.

Lung stents, also known as airway stents or tracheobronchial stents, are interventional pulmonology devices used to maintain airway patency in patients with malignant or benign central airway obstruction, tracheobronchomalacia, post-transplant airway complications, fistulas, and stenosis. Their clinical relevance is increasing as hospitals and specialty centers expand minimally invasive bronchoscopy capabilities for patients who require rapid symptom relief, improved ventilation, and palliative airway management. Silicone stents, self-expanding metallic stents, hybrid designs, covered stents, and patient-specific solutions are shaping a dynamic lung stents market where device selection is driven by anatomy, indication, removability, migration risk, granulation tissue formation, and procedural expertise. Demand is closely linked to rising respiratory disease burden, lung cancer prevalence, aging populations, tuberculosis-related airway damage in some regions, and greater adoption of therapeutic bronchoscopy. At the same time, regulatory scrutiny, post-procedure surveillance needs, and the importance of multidisciplinary care are reinforcing the need for evidence-based product development, physician training, and long-term safety monitoring.

Transformative Shifts in the Lung Stents Landscape

The lung stents landscape is being reshaped by the shift from emergency airway rescue toward planned, image-guided, and multidisciplinary airway management. Interventional pulmonologists, thoracic surgeons, anesthesiologists, oncologists, and critical care teams are increasingly collaborating to determine when stenting provides durable clinical value versus when tumor debulking, balloon dilation, laser therapy, cryotherapy, radiation, or systemic therapy should be prioritized. Material innovation is a central transformation, with continued evaluation of silicone, nitinol, covered metallic, biodegradable, drug-eluting, and customized 3D-modeled stents to reduce complications such as migration, mucus plugging, restenosis, fracture, infection, and tissue overgrowth. Procedure settings are also evolving as advanced bronchoscopy suites integrate rigid and flexible bronchoscopy, fluoroscopy, cone-beam CT, endobronchial ultrasound, and real-time imaging support. Another defining shift is the growing emphasis on patient-specific airway geometry, particularly for complex bifurcation lesions, mainstem bronchus obstruction, and post-surgical airway abnormalities. These trends are moving lung stent utilization toward precision airway intervention supported by standardized follow-up protocols and robust clinical evidence.

Cumulative Impact of Artificial Intelligence on Lung Stents

Artificial intelligence is beginning to influence the lung stents ecosystem by strengthening decision support across diagnosis, planning, device design, and follow-up. AI-enabled imaging analysis can support detection and characterization of airway narrowing on CT scans, assist in measuring stenosis length and diameter, and help clinicians evaluate relationships between lesions, carina, lobar bronchi, and adjacent structures. In procedural planning, machine learning tools can contribute to patient-specific simulation, airway segmentation, and virtual bronchoscopy workflows that improve sizing accuracy and reduce avoidable device-related complications. AI also supports the development of customized stents by improving segmentation for 3D modeling and enabling more consistent translation from imaging data to device geometry. In post-placement monitoring, algorithmic analysis of imaging, bronchoscopy notes, oxygenation trends, and symptom data may help flag complications such as stent migration, obstruction, mucus retention, infection, or recurrent tumor compression. However, responsible adoption requires validated datasets, clinician oversight, cybersecurity safeguards, bias mitigation, and compliance with medical device software regulations. The cumulative impact of AI is therefore not device replacement but improved precision, workflow efficiency, complication surveillance, and evidence generation in airway stenting.

Key Regional Insights Across the Lung Stents Market

Asia-Pacific is gaining strategic importance in lung stents due to high respiratory disease burden, expanding cancer care infrastructure, and increasing availability of advanced bronchoscopy in major urban hospitals across China, India, Japan, South Korea, Australia, and Southeast Asia. North America remains a highly mature environment for lung stent adoption, supported by established interventional pulmonology programs, advanced imaging access, structured cancer care pathways, and strong procedural training networks in the United States and Canada. Latin America shows selective growth in tertiary centers, where airway stenting is increasingly used for malignant obstruction, tuberculosis-related stenosis, and complex benign airway disease, although access can vary by reimbursement, specialist availability, and hospital infrastructure. Europe benefits from strong clinical guideline adoption, multidisciplinary thoracic care, and high procedural standards, with Germany, the United Kingdom, France, Italy, and Spain contributing to advanced bronchoscopic intervention. The Middle East is expanding interventional pulmonology capacity through investment in specialty hospitals, oncology centers, and medical tourism hubs, particularly where respiratory disease, smoking-related conditions, and cancer care demand are rising. Africa presents a mixed landscape: leading urban centers are building bronchoscopy capabilities, while broader adoption is constrained by equipment availability, trained personnel, and referral pathway limitations. Across all regions, the strongest opportunities are linked to training, device availability, complication management, and integration of lung stents into comprehensive airway obstruction care.

Key Group Insights for Lung Stents Adoption

Within ASEAN, lung stents adoption is influenced by uneven access to interventional pulmonology, a high burden of respiratory infections in some member states, and growing investment in tertiary cancer and pulmonary care centers in markets such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is characterized by significant healthcare infrastructure investment, rising demand for advanced thoracic oncology and pulmonary services, and the expansion of specialized centers capable of complex airway procedures. The European Union provides a structured environment for lung stent evaluation through harmonized medical device regulation, strong hospital-based evidence generation, and established cross-border clinical standards, although procurement and reimbursement remain country-specific. BRICS countries represent a diverse but influential group where population scale, respiratory disease burden, lung cancer incidence, and public-private hospital expansion are driving demand for airway intervention, especially in China, India, Brazil, Russia, and South Africa. G7 countries remain central to clinical innovation, regulatory benchmarking, specialist training, and high-acuity use of silicone and metallic airway stents, supported by advanced imaging and multidisciplinary cancer care systems. NATO countries overlap substantially with developed hospital networks in North America and Europe, where procurement resilience, supply chain continuity, and critical care readiness have become more prominent considerations for respiratory devices. Across these groups, the key differentiators are clinical training density, regulatory pathways, reimbursement reliability, and access to advanced bronchoscopy infrastructure.

Key Country Insights in Lung Stents

The United States leads in advanced airway intervention through extensive interventional pulmonology expertise, high use of multidisciplinary thoracic oncology pathways, and broad access to rigid and flexible bronchoscopy in academic and specialty hospitals. Canada benefits from centralized specialty care and evidence-based clinical practice, with lung stents used in major centers for malignant and complex benign airway obstruction. Mexico is expanding access in high-complexity hospitals, especially for cancer-related airway compromise, while disparities in regional infrastructure shape procedural availability. Brazil has a significant respiratory and oncology care burden, with major urban hospitals supporting increasingly sophisticated airway management. The United Kingdom emphasizes guideline-driven respiratory and cancer care, enabling structured evaluation of airway stenting in complex cases. Germany is a major European hub for interventional pulmonology, supported by advanced hospital infrastructure, engineering expertise, and specialized thoracic centers. France maintains strong multidisciplinary respiratory care and uses airway stents within carefully selected therapeutic bronchoscopy pathways. Russia presents demand linked to oncology, tuberculosis sequelae, and tertiary respiratory care, although access varies across geography. Italy and Spain both show strong thoracic and pulmonary care capabilities, with airway stenting integrated into advanced bronchoscopy and cancer programs. China is rapidly expanding interventional pulmonology capacity, supported by large patient volumes, hospital modernization, and increasing thoracic oncology services. India shows rising demand driven by lung cancer, post-infectious airway stenosis, and expanding private-sector specialty care, though affordability and geographic access remain important constraints. Japan has mature respiratory care, advanced imaging, and high procedural quality, supporting precise use of lung stents in selected patients. Australia benefits from well-developed tertiary referral systems and strong clinical governance for complex airway disease. South Korea combines advanced medical technology adoption, high-quality hospital systems, and growing interventional pulmonology expertise, making it an important Asia-Pacific market for airway stenting innovation and clinical adoption.

Actionable Recommendations for Lung Stents Industry Leaders

Industry leaders should prioritize clinically differentiated lung stent designs that address the most persistent procedural challenges: migration, mucus retention, granulation tissue, restenosis, removability, and anatomical fit. Product development should be guided by real-world clinical workflows, including rigid and flexible bronchoscopy compatibility, predictable deployment, radiopacity, ease of repositioning, and safe removal when needed. Investment in physician education is essential, particularly in regions where interventional pulmonology capacity is developing and procedural outcomes depend heavily on sizing, placement technique, and follow-up. Organizations should strengthen evidence generation through post-market registries, prospective observational studies, standardized complication reporting, and long-term surveillance of benign and malignant indications. AI-enabled planning tools, 3D airway modeling, and customized stent workflows should be pursued where regulatory validation and clinical benefit can be clearly demonstrated. Supply chain strategies must account for urgent-use scenarios, multiple stent sizes, hospital inventory constraints, and regional regulatory requirements. Leaders should also collaborate with clinicians to develop protocols for patient selection, surveillance bronchoscopy, mucus management, infection prevention, and stent removal. The most resilient strategies will combine device innovation, training, compliance, and measurable clinical utility.

Research Methodology for Lung Stents Analysis

A rigorous lung stents research methodology should combine primary clinical insights, secondary evidence review, regulatory intelligence, and structured qualitative analysis. Primary inputs should include interviews with interventional pulmonologists, thoracic surgeons, respiratory physicians, hospital procurement teams, clinical engineers, and regulatory specialists to understand procedure patterns, device preferences, complications, and adoption barriers. Secondary research should evaluate peer-reviewed journals, clinical guidelines, medical device safety communications, regulatory databases, public health publications, hospital protocol documents, and respiratory disease epidemiology from recognized health authorities. The methodology should distinguish between silicone, metallic, covered, hybrid, biodegradable, and customized airway stents, while also segmenting indications such as malignant central airway obstruction, benign stenosis, tracheobronchomalacia, fistula management, and post-transplant complications. Data validation should rely on triangulation across clinical literature, expert input, and regulatory evidence, with careful exclusion of unsupported claims. Since lung stent performance depends on patient selection and procedural technique, interpretation should account for care setting, specialist availability, imaging access, and follow-up infrastructure. Ethical handling of clinical data, transparent assumptions, and continuous evidence updates are essential for credible analysis.

Conclusion: Advancing Precision Airway Stenting

Lung stents are becoming an increasingly important component of modern airway management as clinicians seek minimally invasive options to restore patency, relieve dyspnea, and support complex thoracic care. The market is being shaped by advances in interventional pulmonology, improved imaging, patient-specific device concepts, and the emerging role of AI in planning and surveillance. Regional adoption remains closely tied to specialist training, hospital infrastructure, reimbursement systems, and access to advanced bronchoscopy. While innovation is accelerating, long-term success depends on reducing complications, improving stent fit, strengthening clinical evidence, and ensuring appropriate patient selection. Industry stakeholders that align product development with real-world procedural needs, regulatory expectations, and multidisciplinary care pathways will be best positioned to support safer and more effective lung stent use worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Lung Stents Market, by Product Type

• 7.1. Bioresorbable Stents
  • 7.1.1. Magnesium-Based
  • 7.1.2. PLLA-Based
• 7.2. Drug-Eluting Stents
• 7.3. Metallic Stents
• 7.4. Polymer Stents
  • 7.4.1. Biodegradable
  • 7.4.2. Nondegradable

8. Lung Stents Market, by Indication

• 8.1. Airway Obstruction
• 8.2. Malacia
• 8.3. Tracheobronchial Stenosis
• 8.4. Tumor
  • 8.4.1. Benign Tumor
  • 8.4.2. Malignant Tumor

9. Lung Stents Market, by Material

• 9.1. Nitinol
• 9.2. Polymer-Based
  • 9.2.1. Poly-L-Lactic Acid
  • 9.2.2. Polycarbonate Urethane
• 9.3. Stainless Steel

10. Lung Stents Market, by Patient Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Lung Stents Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Clinics
• 11.3. Hospitals

12. Lung Stents Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Lung Stents Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Lung Stents Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Allium Medical Solutions Ltd.
• 16.2. Alvimedica
• 16.3. Balton Sp. z o.o.
• 16.4. Bentley Innomed GmbH
• 16.5. Bess Medizintechnik GmbH
• 16.6. Boston Medical Products, Inc.
• 16.7. Boston Scientific Corporation
• 16.8. C. R. Bard, Inc.
• 16.9. Cook Group Incorporated
• 16.10. E. Benson Hood Laboratories, Inc.
• 16.11. EFER ENDOSCOPY
• 16.12. ELLA-CS s.r.o.
• 16.13. Endo-Flex GmbH
• 16.14. Fuji Systems Corporation
• 16.15. Hobbs Medical Inc.
• 16.16. Hyundai Medical Co., Ltd.
• 16.17. M.I. Tech Co., Ltd.
• 16.18. Medorah Meditek Pvt. Ltd.
• 16.19. Medtronic plc
• 16.20. Merit Medical Systems, Inc.
• 16.21. Micro-Tech Co., Ltd.
• 16.22. Mitra Industries Private Limited
• 16.23. Novatech SA
• 16.24. Olympus Corporation
• 16.25. S&G Biotech Inc.
• 16.26. Sinolinks Medical Innovation
• 16.27. Standard Sci Tech Inc.
• 16.28. Stening SRL
• 16.29. Taewoong Medical Co., Ltd.
• 16.30. W. L. Gore & Associates, Inc.